A phase 3, prospective, randomized, double-blind, placebo-controlled, multicenter, tolerance and efficacy study of RSD1235 in subjects with atrial fibrillation or atrial flutter

Trial Profile

A phase 3, prospective, randomized, double-blind, placebo-controlled, multicenter, tolerance and efficacy study of RSD1235 in subjects with atrial fibrillation or atrial flutter

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Vernakalant (Primary)
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Registrational; Therapeutic Use
  • Acronyms ACT-3; ACT-III
  • Most Recent Events

    • 02 Sep 2010 Vernakalant has been approved in the EU, Iceland and Norway based on the results of ACT-I, -II and -III and AVRO trials, according to a Merck media release.
    • 19 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top